Remove

Under the Paperwork Reduction Act of 1995, no persons are required to res

INFORMATION DISCLOSUR	Ξ
STATEMENT BY APPLICAN	Г
( Not for submission under 37 CFR 1.99	)

Application Number		
iling Date		
First Named Inventor Krue		9
Art Unit		
Examiner Name		
Manager Danket Mount		

1									
3 3470026 1969-09-30 Juda et al.  4 3085053 1963-04-09 Taylor  If you wish to add additional U.S. Patent citation information please click the Add button. Add J. U.S.PATENT APPLICATION PUBLICATIONS (Serove)  Examinor Cite Publication Number Kind Publication Name of Patentee or Applicant Pages Columns L. Relevant Passage.									
If you wish to add additional U.S. Patent citation information please click the Add button.  Add  U.S.PATENT APPLICATION PUBLICATIONS  Examinor Cite  Publication Number  Kind  Publication  Name of Patentee or Applicant  Regionary Pages, Columns L.  Regionary Pages, Columns L.  Regionary Pages, Columns L.									
If you wish to add additional U.S. Patent citation information please click the Add button.    Add   U.S.PATENT APPLICATION PUBLICATIONS   Remove									
U.S.PATENT APPLICATION PUBLICATIONS  Examinor Cite Publication Number City Publication Name of Patentee or Applicant Relevant Passage									
Examiner Cite Publication Number Cind Publication Name of Patentee or Applicant Relevant Passage									
Examiner Cite Publication Number Rind Publication Name of Patenties of Applicant Relevant Passage									
1									
If you wish to add additional U.S. Published Application citation information please click the Add button. Add									
FOREIGN PATENT DOCUMENTS Remove	FOREIGN PATENT DOCUMENTS Remove								
Examiner Citle Foreign Document Initial* No Number? Code2 i Kind Code6 Date Publication Number of Patiente or Applicant of clied Document									

U.S.PATENTS

	Application Number		
INFORMATION DIGGS COURT	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Krue		si
(Not for submission under 37 CFR 1.99)	Art Unit		
,,	Examiner Name		
	Attorney Docket Numb	er	

	1											
If you wis	h to a	dd add	fitional Forei	gn Pate	nt Document	citation	information pl	ease click the Add	buttor	Add		
NON-PATENT LITERATURE DOCUMENTS Remove												
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Ţ5				
	1 International Search Report dated 06-15-2005, for PCT Application No. PCT/US05/06902											
	2 PCT Written Opinion dated 06-15-2005, for PCT Application No. PCT/US0506992											
If you wish to add additional non-patent literature document citation information please click the Add button Add												
EXAMINER SIGNATURE												
Examiner	Signa	ture						Date Conside	ered			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

See Kind Code of USPTO Petent Documents at twent\_ISETO\_GOL/or MPEP 901.04. \* Enter office that issued the document, by the two-lets of (WPD) Standard 513.) \* For implanees petent focuments, the includance of the pear of the register or twent precede the serial number of the petent document. A produced the period of the petent of the pet

# Application Number Filing Date Filing Date

### CERTIFICATION STATEMENT

i icus	0 300 01	id 1.50 to make	are appropriate ser		

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI.)

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the contraction of the

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Diagon one 37 CER 1 07 and 1 98 to make the appropriate colortion(c)

.7 None

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Robert D.Traver/	Date (YYYY-MM-DD)	2006-09-01
Name/Print	Robert D. Traver	Registration Number	47999

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenian's (Office, U.S. Operatment of Commence, P. 0. Bast 1450, Alexandria, V.32.131-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.231-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.